top of page
  • Writer's pictureFutureMeds

FutureMeds Joins Fortrea’s New Site Advisory Board

Fortrea brings experienced sites, investigators and technology providers together to support trial planning and drive changes that will improve the speed of trial execution, ease study start-up, increase recruitment efficiency and ultimately meet Sponsors' pipeline development needs effectively while boosting patient experience.

The inaugural meeting of Fortrea's New Site Advisory Board took place on December 8, 2023. To evolve the site, sponsor and patient relationships and to improve patient experience, the board will target changes in technology, operational delivery, commercial terms and community engagement.

By putting sites and investigators at the forefront of clinical trial planning, and leveraging their perspectives, Fortrea’s Site Advisory Board aims to drive changes that will improve the speed of trial execution, ease study start up, and increase recruitment efficiency. The board will be responsible for providing insights and feedback on proposed strategies and solutions related to sites, patients, trial operations, and relevant technology, enabling Sponsors to meet their pipeline development needs effectively.

“Incorporating the perspectives and voice of patients, investigators, and sites and leveraging their valuable insights in the planning process will put Fortrea in a pole position to bring new therapies to the market. We are honoured to join other leading industry experts and Mike Clay’s team and work together to address persisting challenges in clinical research.” 

Dr Radoslaw Janiak, CEO at FutureMeds


“FutureMeds is delighted to join Fortrea’s Site Advisory Board, which aims to build better understanding between key stakeholders in the clinical research industry and boost patient and client outcomes.” added the CEO at FutureMeds.

About the Site Advisory Board

Fortrea focuses on delivering customised solutions that provide strategic flexibility and operational focus, enabling their clients to meet their pipeline development needs effectively. ‘Working with investigators and sites to help the industry solve the last-mile challenges of patient engagement and operational delivery is a foundation of this strategy,’ states Fortrea’s press release.

“Sites are critical to the industry at every stage of clinical development, and they traditionally have faced hard-to-solve challenges in clinical trials alone. We welcome their insights in protocol design and actively engage them in early conversations with our operational teams and sponsors to quickly establish the most efficient, patient-focused trial plans.” 

– Mike Clay, Vice President, Development Strategy and Growth at Fortrea 

Fortrea’s Site Advisory Board includes leaders and experts from Circuit Clinical, Elligo Health Research, FutureMeds, Javara Research, MD Anderson Center, ObjectiveHealth, Pratia S.A. and Velocity Clinical Research, representing 440 sites across more than 25 therapeutic areas and nine countries and providing access to diverse patient communities.

“The formation of the Site Advisory Board marks an acceleration of our site-focused strategy and includes representation from incredibly impressive leaders, creating a think tank for our industry. The Board will also serve as a cornerstone of our ability to respond to sponsors with confidence and speed, working together to develop efficient operational plans and provide sponsors with a high degree of confidence in speed of patient recruitment and overall trial delivery.”

– Mike Clay, vice president, Development Strategy and Growth at Fortrea 

“Strong CRO and site and investigator relationships are the backbone of effective clinical research. Fortrea’s commitment to understanding and balancing these relationships is a testament to their dedication to advancing medical research,” added Cameron Glen, VP of Global Business Development at FutureMeds

“We are particularly grateful for the support and vision of Mike Clay, SVP, and Constance Jung-Stach, Head of EMEA Site Engagement and Partnership, whose insights have been invaluable in shaping this partnership.” 

About Fortrea

Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development and patient access solutions to the life sciences industry. They partner with emerging and large biopharmaceutical, medical device and diagnostic companies to drive healthcare innovation that accelerates life-changing therapies to patients in need. 

Fortrea provides phase I-IV clinical trial management, clinical pharmacology, differentiated technology-enabled trial solutions and post-approval services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigour, exceptional insights and a strong investigator site network. 

Fortrea’s talented and diverse team of about 19,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at and follow them on LinkedIn and X (formerly Twitter) @Fortrea.


About FutureMeds 

Specialising in conducting clinical trials, FutureMeds is the 1st European Independent Dedicated DCT Site Network offering high levels of traditional and Decentralised Clinical Trial capabilities across the whole network and home nursing solutions in 18 European countries.

FutureMeds is driven by a purpose to connect a global healthcare community and help bring quicker access to life-changing medications and therapies to all those who need them worldwide.

FutureMeds’ Dedicated Research Site (DRS) teams serve as the company’s service foundation. DRS team’s execution capabilities help pharmaceutical companies and contract research organisations accelerate study timelines, streamline processes, lower costs, improve data quality and ultimately help speed up drug development and patient access to new treatments.

FutureMeds @home, the company’s Decentralised Clinical Trial solution, provides pharmaceutical companies, contract research organisations and other partners with powerful insights, tools, teams & support, enabling them to simplify patient access to trials and boost recruitment, engagement and retention.

Through its acquisitions, partnerships and a strategic focus on patient experience, FutureMeds brings opportunities to diverse European patient populations to participate in clinical research under the medical supervision of qualified physicians and health care professionals.

Follow us on LinkedIn

Follow FutureMeds on LinkedIn and join a growing group of engaged, passionate healthcare and pharmaceutical professionals who are on a mission to accelerate the drug development process and achieve regulatory approval faster so patients can safely access the very latest treatments as soon as possible.


התגובות הושבתו לפוסט הזה.
bottom of page